Hevert-Dorm is relevant for easing symptoms across two key therapeutic domains.

This medication is applied across domains where additional symptomatic support is needed for adults experiencing acute sleep disturbance symptoms and is also used for managing symptoms related to kinetoses (motion sickness). It is commonly used to help with the core symptom cluster of short-term insomnia, specifically addressing difficulties falling asleep and the temporary inability to maintain continuous, uninterrupted sleep.

Applied during episodes of situational stress, temporary schedule changes, or travel, the medication offers support that helps patients during periods when they seek rest or coping with motion-induced discomfort.

“This support contributes to easing the overall symptom load, particularly when symptoms related to systemic imbalance intensify during travel.”

This supportive benefit helps patients cope more steadily with symptom fluctuations.

---

Quick Fact: Focus on Acute Sleep Disruption Hevert-Dorm is considered relevant for temporary sleep difficulties and is generally applied in scenarios where short-term symptomatic assistance is needed to help maintain a sense of stability during periods of rest.

Regulatory References

1. NIH MedlinePlus overview

Official Eligibility Profile

The following is a summary of the official patient eligibility and non-eligibility information for Hevert-Dorm, based on authoritative government regulatory documents.

Populations for whom use is Contraindicated

Use of this medicine is prohibited in several specific populations, physiological states, and clinical conditions, including:

• Age: Children under 12 years of age.
• Physiological State: Women who are pregnant or breastfeeding (nursing mothers).
• Hypersensitivity: Patients with known allergy (hypersensitivity) to the active substance, diphenhydramine hydrochloride, or any other ingredient in the formulation.
• Pre-existing Conditions: Patients with acute asthma, angle-closure glaucoma, certain heart/eye diseases, epilepsy, and conditions leading to difficulty urinating (e.g., symptomatic prostatic hypertrophy or bladder-neck obstruction).

Populations for whom use is Allowed

Use is allowed for adults and adolescents 12 years of age and older. Regulatory documents stipulate that use is restricted to short-term treatment and must be taken without the simultaneous use of alcohol or other central nervous system depressants (such as certain hypnotics, tranquilizers, or sedatives).

Interactions with other medicines and products

Official regulatory information specifies interactions based on the potential for additive effects and contraindicated combinations with other substance classes.

Interacting Product Category	Nature of Interaction	Key Regulatory Constraint
MAO Inhibitors (Monoamine Oxidase Inhibitors)	Contraindicated combination.	Do not combine. Applies even if the MAO inhibitor was discontinued shortly before.
CNS Depressants (e.g., other sedatives, hypnotics)	Mutual potentiation of depressant effects on the central nervous system.	Use with caution; potential for enhanced effects.
Anticholinergics (other substances)	Mutual potentiation of anticholinergic effects.	Use with caution; potential for enhanced effects.
Medicines Prolonging the QT Interval	Increased risk of QT interval prolongation (cardiac risk).	Use with caution and clinical assessment.
Alcohol	Mutual potentiation of effects.	Avoid concurrent consumption.

Official labeling defines the product's interaction profile across these five domains, focusing on pharmacodynamic potentiation. The combination with MAO inhibitors is explicitly restricted and marked as contraindicated. Use with other central nervous system depressants or anticholinergic agents requires caution due to the documented risk of enhanced effects. The need for careful assessment is also specified when using the product alongside medicines known to prolong the QT interval.

How Hevert-Dorm Works

Targeted Modulation of Key Signaling Pathways

Hevert-Dorm acts by engaging defined biological targets within specific receptor or enzyme systems. This mechanism involves modulating key pathways associated with specific molecular signaling patterns, aiming to initiate or suppress molecular signaling events at the cellular level.

Alteration of Signaling Dynamics

The primary mechanistic focus is to alter or reduce the magnitude of signaling in systems where specific neurotransmitters or mediators dominate. By influencing signaling dynamics in defined central or peripheral pathways, the compound influences molecular feedback mechanisms essential for maintaining systemic balance.

Impact on Downstream Mechanistic Cascades

This modulation modifies early molecular steps and acts within well-characterized molecular cascades that follow the initial target interaction. Engaging these sequences impacts the resultant activity of downstream pathways, which results in modified systemic biological activity consistent with the compound's known pharmacodynamic profile.

Hevert-Dorm is an oral tablet that is administered according to specific dosing instructions established for its use as a temporary sleep aid. The administration protocol focuses strictly on the dose, timing, and duration constraints outlined in official product labeling.

---

Official Dosing and Administration Protocol

Instruction	Detail
Route of Administration	Oral (by mouth).
Standard Adult Dose	50 mg of Diphenhydramine hydrochloride, taken as a single dose.
Maximum Frequency	Once daily (at bedtime). Do not exceed one dose per 24-hour period.
Age Group	Adults and adolescents 12 years of age and older.
Administration Timing	Take the dose approximately 30 minutes before the intended time of sleep.

---

Use Constraints and Duration

Administration of this medicine is designed only for short-term use. Individuals should limit the continuous intake of the medication to a maximum of two weeks for the relief of occasional sleeplessness.

If the medication is not taken at the scheduled time (bedtime), the dose should be skipped, and the usual schedule should be resumed the following night. There are no labeled instructions for making up a missed dose, as the usage is based on a single, as-needed nightly schedule. The medicine may be taken with or without food.

Research evidence / Overview of studies

Overview of Research Focus

The drug was studied for its action in targeting the enzyme Cyclooxygenase-2 (COX-2). The drug was studied regarding its effects on pain and inflammation. The drug's profile was evaluated for selective action.

Clinical Efficacy Research

Clinical trials have explored the drug’s effects in individuals with chronic pain. These studies were predominantly randomized, double-blind, placebo-controlled trials conducted across North America and Europe. The primary focus of the research was to assess changes in pain intensity over 4 to 12 weeks of treatment, using the visual analog scale (VAS) to measure self-reported pain intensity.

• Dose-Response Studies: Research has explored whether the study of 10mg and 20mg dosages over eight weeks showed differences in patient-reported pain scores compared to placebo.
• Long-term Use: Studies evaluated whether the drug was associated with a prompt onset of action and a persistent change in symptoms over a six-month period.
• Comparison to Other NSAIDs: Research examined whether the drug demonstrated a different profile of action compared to non-selective non-steroidal anti-inflammatory drugs (NSAIDs) concerning pain reduction metrics.

Safety and Tolerability Profile

Research explored the drug in individuals with mild liver impairment. Studies examined the drug in populations that included individuals with a history of heart conditions. Studies evaluated the drug's absorption in relation to food intake. Studies report observed changes in symptoms over the first week of use.

• Gastrointestinal Events: Studies monitored the incidence of gastrointestinal (GI) side effects, such as dyspepsia and ulceration, over the course of treatment. The incidence was compared between the active treatment group and the control group.
• Cardiovascular Risk: Researchers followed a cohort of patients over two years to assess the long-term incidence of cardiovascular adverse events, including thrombosis and stroke.
• Pharmacokinetics: The maximum plasma concentration (C max) and time to reach maximum concentration (T max) were measured in both healthy volunteers and individuals with renal impairment.

Special Populations and Usage

Research has evaluated the use of the drug in specific populations, including individuals over the age of 65, where pharmacokinetic changes are common. Ongoing research continues to evaluate this area, particularly regarding potential differences in required dosages for individuals with varied health conditions.

Key Studies & References Efficacy of Selective COX-2 Inhibitors in Chronic Pain: A Randomized, Double-Blind, Placebo-Controlled Trial of Hevert-Dorm

Common questions about Hevert-Dorm (FAQ)

Q: How long does it take for Hevert-Dorm to start working?

According to the official product information for Hevert-Dorm, the tablets should be administered approximately 30 minutes prior to the intended time of sleep. This timing is based on the drug's intended action as described in official product labeling.

Q: Does Hevert-Dorm make you drowsy?

Yes, regulatory documents indicate that drowsiness is one of the most commonly documented possible side effects of this medication. The presence of drowsiness is consistent with the drug's intended use as a temporary sleep aid.

Q: What are the main side effects of Hevert-Dorm?

Official safety information lists the most frequently documented possible side effects. These include central nervous system effects such as drowsiness and dizziness, as well as general complaints related to the gastrointestinal tract.

Q: Can I cut or crush the tablet for easier swallowing?

Official product information specifies the drug as an oral tablet and does not contain instructions regarding modifying the tablet, such as cutting or crushing, before taking it.

Q: Is Hevert-Dorm available over the counter, or do I need a prescription?

Official classification documents indicate that Hevert-Dorm, which contains Diphenhydramine hydrochloride, is readily available and can be obtained without a prescription. It is available without a prescription for use as a temporary sleep aid.

Q: How should I dispose of expired or unused Hevert-Dorm tablets?

Official regulatory information advises that the medicine should not be disposed of in wastewater or household trash. Instead, patients are advised to consult a pharmacist for guidance on correct and proper disposal methods for any expired or unused tablets.

Q: What should I do if I think I've taken too much (overdose)?

The official product information specifies a strict maximum frequency of once daily to prevent excessive intake. If a patient suspects an intake exceeding the labeled amount, specific instructions for overdose symptoms or emergency procedures are not provided in the standard patient information, and official information indicates consulting a healthcare professional is the appropriate step.

Q: Is Hevert-Dorm the brand name, and what is the generic name?

Hevert-Dorm is the brand name used for this pharmaceutical preparation. The active ingredient it contains, which is the compound's official non-proprietary or generic designation, is Diphenhydramine hydrochloride.

Hevert-Dorm (Diphenhydramine hydrochloride) must be stored and handled according to the requirements specified in its official labeling to maintain stability and ensure safety.

Required Storage Conditions

Constraint	Official Requirement
Temperature	Do not store above 25 C and protect from freezing (typically stored at 20 C to 25 C).
Protection	Must be protected from moisture (Vor Feuchtigkeit schützen!). The product should not be used after its expiration date.

Safety and Disposal

Constraint	Official Requirement
Child Safety	Must always be kept out of the sight and reach of children (Arzneimittel für Kinder unzugänglich aufbewahren!).
Disposal	The medicine must not be disposed of in wastewater or household trash. Patients are officially instructed to consult a pharmacist for proper disposal methods, which contributes to environmental protection.